查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947928

中樞神經系統治療市場分析及預測（至2035年）：依類型、產品、技術、應用、最終用戶、製程、設備、階段及給藥途徑分類

Central Nervous System Therapeutics Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Process, Device, Stage, Mode
出版日期: | 出版商: Global Insight Services | 英文 380 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計到2034年，中樞神經系統治療市場規模將從2024年的1,363億美元成長至2,885億美元，複合年成長率約為12.1%。該市場涵蓋針對阿茲海默症、帕金森氏症和多發性硬化症等神經系統疾病的治療方案。生物技術的進步、中樞神經系統疾病盛行率的上升以及人口老化加劇是推動該市場成長的主要因素。藥物遞送系統和個人化醫療的創新至關重要，其重點在於提高療效和改善患者預後。監管支持和研發投入的增加進一步推動了市場成長，為相關人員創造了豐厚的成長機會。

中樞神經系統治療市場正經歷顯著成長，這主要得益於神經系統疾病盛行率的上升和創新治療方法的研發。神經退化性疾病領域，尤其是阿茲海默症和帕金森氏症，由於新型藥物的研發和診斷技術的進步，處於領先地位。精神疾病治療，特別是憂鬱症和焦慮症的治療，也緊隨其後，反映出人們對心理健康的日益關注和認可。生物製藥和小分子療法是關鍵的細分市場，其中生物製藥因其定向和副作用較小而備受關注。小分子療法領域保持著強勁的成長勢頭，提供經濟高效的解決方案和廣泛的適用性。基因療法和幹細胞療法正在迅速發展，並有望對慢性神經系統疾病產生變革性影響。對個人化醫療日益成長的需求凸顯了為每位患者制定最佳化治療方案的必要性。預計不斷增加的研究經費以及製藥公司與研究機構之間的策略聯盟將進一步推動創新和市場成長。

市場區隔
按類型 神經退化性疾病、神經血管疾病、精神疾病、感染疾病、中樞神經系統創傷、自體免疫疾病、神經腫瘤學
產品 小分子化合物、生物製藥、基因療法、細胞療法、神經刺激設備、神經保護劑
科技 CRISPR、 RNA干擾、幹細胞療法、奈米技術、生物標記、人工智慧
目的 藥物研發、診斷、外科手術、復健、遠端醫療、個人化醫療
最終用戶 醫院、診所、研究機構、生物製藥公司、學術機構
流程 臨床試驗、臨床前研究、藥物發現、監管核准和商業化
裝置 植入式設備、穿戴式裝置、診斷設備和治療設備
步 早期研究、臨床前研究、臨床研究及商業化​​上市
給藥途徑 口服、注射、外用、吸入

中樞神經系統治療市場正經歷著由治療創新和策略定價模式驅動的市場佔有率動態變化。隨著大型製藥和生技公司推出突破性治療方法，新產品的上市正在重塑市場結構。這些進展不僅改善了患者的治療效果，也推動了競爭激烈的定價策略。市場對先進療法的需求激增，促使各公司加速研發投入以維持競爭優勢。競爭基準研究揭示了主要產業參與者之間的激烈競爭，策略聯盟和併購正在重塑競爭格局。監管影響至關重要，嚴格的指導方針規範市場准入和產品核可流程。北美和歐洲的法規結構仍然是影響市場動態和競爭策略的關鍵因素。這項全面的分析強調了了解監管影響和競爭定位對於有效駕馭中樞神經系統治療市場的重要性。

主要趨勢和促進因素：

受全球人口老化和神經系統疾病盛行率上升的推動，中樞神經系統（CNS）治療市場正經歷顯著成長。生物製藥和基因療法的進步是關鍵趨勢，為傳統上難以治療的CNS疾病提供了極具前景的治療選擇。人工智慧在藥物研發的應用正在加速新型療法的開發，並提升精準醫療水準。此外，以病人為中心的醫療模式日益受到重視，推動了數位療法的興起，這些療法是對傳統治療方法的補充。醫療保健技術和基礎設施投資的不斷增加也為這一轉變提供了支持。監管機構也在簡化創新CNS療法的核准流程，以加速其市場准入。新興市場蘊藏著許多機遇，這些市場的醫療保健覆蓋範圍不斷擴大，人們對CNS疾病的認知也不斷提高。專注於個人化醫療和標靶治療的公司有望佔據可觀的市場佔有率。製藥公司和科技公司之間的合作正在透過數位平台推動進一步創新，這些平台能夠實現對CNS疾病的即時監測和管理。這種充滿活力的環境有望實現持續成長，尤其是在開發出滿足未被滿足的治療方法需求的新療法之後。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 神經退化性疾病
    • 神經血管疾病
    • 精神疾病
    • 感染疾病
    • 創傷性中樞神經系統損傷
    • 自體免疫疾病
    • 神經腫瘤學
  • 市場規模及預測：依產品分類
    • 低分子化合物
    • 生物製藥
    • 基因治療
    • 細胞療法
    • 神經刺激設備
    • 神經保護劑
  • 市場規模及預測：依技術分類
    • CRISPR
    • RNA干擾
    • 幹細胞療法
    • 奈米科技
    • 生物標記
    • 人工智慧
  • 市場規模及預測：依應用領域分類
    • 藥物研發
    • 診斷
    • 手術介入
    • 復原
    • 遠端醫療
    • 個人化醫療
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診所
    • 研究所
    • 生物製藥公司
    • 學術機構
  • 市場規模及預測：依製程分類
    • 臨床試驗
    • 臨床前研究
    • 藥物發現
    • 監管部門核准
    • 商業化
  • 市場規模及預測：依設備分類
    • 植入式裝置
    • 穿戴式裝置
    • 診斷設備
    • 治療設備
  • 市場規模及預測：依階段分類
    • 初步研究
    • 臨床前
    • 臨床
    • 上市
  • 市場規模及預測：依管理途徑
    • 口服
    • 注射
    • 外用
    • 吸入

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Biogen
  • Jazz Pharmaceuticals
  • UCB
  • Alkermes
  • Ipsen
  • Lundbeck
  • Acadia Pharmaceuticals
  • H. Lundbeck
  • Supernus Pharmaceuticals
  • Neurocrine Biosciences
  • Sage Therapeutics
  • Amneal Pharmaceuticals
  • Otsuka Pharmaceutical
  • Sumitomo Pharma
  • Zogenix
  • Acorda Therapeutics
  • Intra-Cellular Therapies
  • GW Pharmaceuticals
  • Eisai
  • Cortexyme

第9章：關於我們

簡介目錄
Product Code: GIS32222

Central Nervous System Therapeutics Market is anticipated to expand from $136.3 billion in 2024 to $288.5 billion by 2034, growing at a CAGR of approximately 12.1%. The Central Nervous System Therapeutics Market encompasses treatments targeting neurological disorders, including Alzheimer's, Parkinson's, and multiple sclerosis. This market is driven by advancements in biotechnology, increasing prevalence of CNS disorders, and a growing geriatric population. Innovations in drug delivery systems and personalized medicine are pivotal, with a focus on improving efficacy and patient outcomes. Regulatory support and rising investment in R&D further propel market growth, presenting lucrative opportunities for stakeholders.

The Central Nervous System Therapeutics Market is experiencing significant advancements, fueled by an increasing prevalence of neurological disorders and innovative treatment modalities. The neurodegenerative diseases segment, particularly Alzheimer's and Parkinson's therapies, is at the forefront, driven by novel drug developments and enhanced diagnostic techniques. Psychiatric disorder treatments, especially for depression and anxiety, follow closely, reflecting an upsurge in mental health awareness and acceptance. Biologics and small molecule therapeutics are leading sub-segments, with biologics gaining prominence due to their targeted action and reduced side effects. The small molecule sector remains robust, offering cost-effective solutions and broad applicability. Gene therapy and stem cell treatments are emerging rapidly, promising transformative impacts on chronic neurological conditions. The demand for personalized medicine is rising, emphasizing the need for tailored therapeutic approaches. Increased research funding and strategic partnerships between pharmaceutical companies and research institutions are expected to drive further innovation and market growth.

Market Segmentation
TypeNeurodegenerative Diseases, Neurovascular Disorders, Psychiatric Disorders, Infectious Diseases, Traumatic CNS Injuries, Autoimmune Disorders, Neuro-oncology
ProductSmall Molecules, Biologics, Gene Therapy, Cell Therapy, Neurostimulation Devices, Neuroprotective Agents
TechnologyCRISPR, RNA Interference, Stem Cell Therapy, Nanotechnology, Biomarkers, Artificial Intelligence
ApplicationDrug Development, Diagnostics, Surgical Intervention, Rehabilitation, Telemedicine, Personalized Medicine
End UserHospitals, Clinics, Research Institutes, Biopharmaceutical Companies, Academic Institutions
ProcessClinical Trials, Preclinical Research, Drug Discovery, Regulatory Approval, Commercialization
DeviceImplantable Devices, Wearable Devices, Diagnostic Equipment, Therapeutic Devices
StageEarly-stage Research, Preclinical Stage, Clinical Stage, Post-Market Surveillance
ModeOral, Injectable, Topical, Inhalation

The Central Nervous System Therapeutics Market is experiencing a dynamic shift in market share, driven by innovation in treatment methodologies and strategic pricing models. New product launches are reshaping the landscape, with pharmaceutical giants and biotech firms introducing groundbreaking therapies. These developments are not only enhancing patient outcomes but also fostering competitive pricing strategies. The market is witnessing a surge in demand for advanced therapeutics, encouraging companies to invest in research and development to maintain a competitive edge. Competition benchmarking reveals a robust rivalry among key industry players, with strategic alliances and mergers shaping the competitive landscape. Regulatory influences are pivotal, with stringent guidelines dictating market entry and product approval processes. The regulatory framework in North America and Europe remains a critical factor, influencing market dynamics and competitive strategies. This comprehensive analysis underscores the importance of understanding regulatory impacts and competitive positioning to navigate the Central Nervous System Therapeutics Market effectively.

Geographical Overview:

The Central Nervous System (CNS) Therapeutics Market is witnessing notable regional growth, each with unique dynamics. North America remains preeminent, driven by substantial investments in research and development and a robust healthcare infrastructure. The presence of leading pharmaceutical companies further bolsters its market position. Europe trails closely, benefitting from strong governmental support for neurological research and increasing prevalence of CNS disorders. The Asia Pacific region is experiencing rapid expansion, fueled by rising healthcare expenditures and an aging population. Emerging economies such as China and India are at the forefront, investing heavily in healthcare advancements. Latin America and the Middle East & Africa are burgeoning markets. Brazil and Mexico are showing increased demand for CNS therapeutics, while the Middle East & Africa are recognizing the potential of CNS treatments in addressing prevalent neurological disorders, thus driving market growth and innovation.

Global tariffs and geopolitical tensions are intricately influencing the Central Nervous System Therapeutics Market. In Japan and South Korea, reliance on imported raw materials for drug manufacturing is prompting a strategic pivot towards enhancing local production capabilities and securing diversified supply sources. China is accelerating its pharmaceutical innovation, driven by export restrictions and a strategic focus on self-reliance. Taiwan, with its robust biotech sector, continues to play a pivotal role but remains sensitive to regional tensions. The global market for CNS therapeutics is experiencing robust growth, propelled by rising prevalence of neurological disorders. By 2035, the market is expected to flourish, contingent upon geopolitical stability and resilient supply chains. Middle East conflicts pose potential risks to global energy prices, indirectly affecting manufacturing and distribution costs.

Key Trends and Drivers:

The Central Nervous System (CNS) Therapeutics Market is experiencing substantial growth, driven by an aging global population and the rising prevalence of neurological disorders. Key trends include advancements in biologics and gene therapy, offering promising treatment options for previously untreatable CNS conditions. The integration of artificial intelligence in drug discovery is accelerating the development of novel therapeutics, enhancing precision medicine approaches. Moreover, there is a growing emphasis on patient-centric care, with digital therapeutics gaining traction to complement traditional treatments. This shift is supported by increasing investments in healthcare technology and infrastructure. Regulatory bodies are also streamlining approval processes for innovative CNS drugs, facilitating faster market entry. Opportunities abound in emerging markets where healthcare access is expanding, and awareness of CNS disorders is increasing. Companies focusing on personalized medicine and targeted therapies are well-positioned to capture significant market share. Collaborations between pharmaceutical companies and tech firms are further driving innovation, with digital platforms offering real-time monitoring and management of CNS conditions. This dynamic landscape is poised for continuous growth, especially as new therapeutic modalities are developed to address unmet medical needs.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Process
  • 2.7 Key Market Highlights by Device
  • 2.8 Key Market Highlights by Stage
  • 2.9 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Neurodegenerative Diseases
    • 4.1.2 Neurovascular Disorders
    • 4.1.3 Psychiatric Disorders
    • 4.1.4 Infectious Diseases
    • 4.1.5 Traumatic CNS Injuries
    • 4.1.6 Autoimmune Disorders
    • 4.1.7 Neuro-oncology
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Small Molecules
    • 4.2.2 Biologics
    • 4.2.3 Gene Therapy
    • 4.2.4 Cell Therapy
    • 4.2.5 Neurostimulation Devices
    • 4.2.6 Neuroprotective Agents
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 CRISPR
    • 4.3.2 RNA Interference
    • 4.3.3 Stem Cell Therapy
    • 4.3.4 Nanotechnology
    • 4.3.5 Biomarkers
    • 4.3.6 Artificial Intelligence
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Drug Development
    • 4.4.2 Diagnostics
    • 4.4.3 Surgical Intervention
    • 4.4.4 Rehabilitation
    • 4.4.5 Telemedicine
    • 4.4.6 Personalized Medicine
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Clinics
    • 4.5.3 Research Institutes
    • 4.5.4 Biopharmaceutical Companies
    • 4.5.5 Academic Institutions
  • 4.6 Market Size & Forecast by Process (2020-2035)
    • 4.6.1 Clinical Trials
    • 4.6.2 Preclinical Research
    • 4.6.3 Drug Discovery
    • 4.6.4 Regulatory Approval
    • 4.6.5 Commercialization
  • 4.7 Market Size & Forecast by Device (2020-2035)
    • 4.7.1 Implantable Devices
    • 4.7.2 Wearable Devices
    • 4.7.3 Diagnostic Equipment
    • 4.7.4 Therapeutic Devices
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Early-stage Research
    • 4.8.2 Preclinical Stage
    • 4.8.3 Clinical Stage
    • 4.8.4 Post-Market Surveillance
  • 4.9 Market Size & Forecast by Mode (2020-2035)
    • 4.9.1 Oral
    • 4.9.2 Injectable
    • 4.9.3 Topical
    • 4.9.4 Inhalation

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Process
      • 5.2.1.7 Device
      • 5.2.1.8 Stage
      • 5.2.1.9 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Process
      • 5.2.2.7 Device
      • 5.2.2.8 Stage
      • 5.2.2.9 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Process
      • 5.2.3.7 Device
      • 5.2.3.8 Stage
      • 5.2.3.9 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Process
      • 5.3.1.7 Device
      • 5.3.1.8 Stage
      • 5.3.1.9 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Process
      • 5.3.2.7 Device
      • 5.3.2.8 Stage
      • 5.3.2.9 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Process
      • 5.3.3.7 Device
      • 5.3.3.8 Stage
      • 5.3.3.9 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Process
      • 5.4.1.7 Device
      • 5.4.1.8 Stage
      • 5.4.1.9 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Process
      • 5.4.2.7 Device
      • 5.4.2.8 Stage
      • 5.4.2.9 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Process
      • 5.4.3.7 Device
      • 5.4.3.8 Stage
      • 5.4.3.9 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Process
      • 5.4.4.7 Device
      • 5.4.4.8 Stage
      • 5.4.4.9 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Process
      • 5.4.5.7 Device
      • 5.4.5.8 Stage
      • 5.4.5.9 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Process
      • 5.4.6.7 Device
      • 5.4.6.8 Stage
      • 5.4.6.9 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Process
      • 5.4.7.7 Device
      • 5.4.7.8 Stage
      • 5.4.7.9 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Process
      • 5.5.1.7 Device
      • 5.5.1.8 Stage
      • 5.5.1.9 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Process
      • 5.5.2.7 Device
      • 5.5.2.8 Stage
      • 5.5.2.9 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Process
      • 5.5.3.7 Device
      • 5.5.3.8 Stage
      • 5.5.3.9 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Process
      • 5.5.4.7 Device
      • 5.5.4.8 Stage
      • 5.5.4.9 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Process
      • 5.5.5.7 Device
      • 5.5.5.8 Stage
      • 5.5.5.9 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Process
      • 5.5.6.7 Device
      • 5.5.6.8 Stage
      • 5.5.6.9 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Process
      • 5.6.1.7 Device
      • 5.6.1.8 Stage
      • 5.6.1.9 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Process
      • 5.6.2.7 Device
      • 5.6.2.8 Stage
      • 5.6.2.9 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Process
      • 5.6.3.7 Device
      • 5.6.3.8 Stage
      • 5.6.3.9 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Process
      • 5.6.4.7 Device
      • 5.6.4.8 Stage
      • 5.6.4.9 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Process
      • 5.6.5.7 Device
      • 5.6.5.8 Stage
      • 5.6.5.9 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Biogen
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Jazz Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 UCB
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Alkermes
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Ipsen
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Lundbeck
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Acadia Pharmaceuticals
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 H. Lundbeck
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Supernus Pharmaceuticals
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Neurocrine Biosciences
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Sage Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Amneal Pharmaceuticals
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Otsuka Pharmaceutical
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Sumitomo Pharma
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Zogenix
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Acorda Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Intra- Cellular Therapies
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 GW Pharmaceuticals
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Eisai
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Cortexyme
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us